Few areas of clinical practice have moved faster than GLP-1 receptor agonist prescribing. In 18 months the conversation has shifted from a quiet specialty intervention to one of the most-prescribed medication categories in primary care, and from open compounding access to a tightening regulatory environment. Clinicians who built their GLP-1 practice in 2024 are not operating under the same rules in 2026.
What follows is a practical orientation to where the legal and regulatory landscape stands now, and what defensible practice looks like in the current environment.
The shortage list and what changed
The compounded GLP-1 era was made possible by the FDA shortage list, which permits 503A and 503B pharmacies to compound versions of drugs in shortage. When the shortages for the brand-name GLP-1s resolved, the legal basis for routine compounding narrowed sharply.
Where the active ingredient remains commercially available, compounding for routine weight or metabolic indications is no longer defensible on shortage grounds. Compounding may still be appropriate for documented clinical need that the commercial product cannot meet, but that documentation must be specific and contemporaneous, not boilerplate.
State-level scrutiny
State medical and pharmacy boards have moved more aggressively in 2025 and 2026 than at any point in the prior decade. The most common areas of scrutiny are telehealth-only prescribing without adequate documentation, asynchronous prescribing without clinical evaluation, pharmacy relationships that look like fee-splitting, and protocols that prescribe identical regimens to large patient populations.
The clinicians attracting attention are not always the bad actors. They are the ones with sloppy documentation. Defensible practice is a documentation practice as much as it is a clinical practice.
"Defensible practice is a documentation practice as much as it is a clinical practice."
What documentation actually requires
For each GLP-1 patient the chart should show a contemporaneous clinical evaluation including indication, contraindications screened, baseline labs and metrics, informed consent specific to the formulation prescribed, a clear monitoring plan, and reassessment at defined intervals. If a compounded product is used, the rationale should be documented at the patient level, not at the protocol level.
None of this is novel. All of it is what prescribing standards have always required. The current environment simply enforces it.
Microdosing, stacks, and the gray edges
Lower-dose GLP-1 protocols and stacking with other peptides are clinically interesting and, for many patients, more tolerable. They also live in a more regulated space than they did in 2024. A microdose protocol prescribed off-label remains within clinician judgment, but the chart must show the reasoning. Stacking with peptides whose regulatory status is unsettled introduces additional exposure.
The clinicians doing this work credibly are the ones who treat each combination as a deliberate clinical decision with its own consent and documentation, not as a default template.
Where this is heading
Expect continued narrowing of the compounded space, continued growth in commercial GLP-1 access including new formulations and indications, and continued attention from boards and payers to the standard of practice. The clinicians who will thrive are the ones treating GLP-1 prescribing with the same care they would apply to a controlled substance: real evaluation, real documentation, real follow-up, and a long-term plan that includes lifestyle and metabolic foundation, not pharmacology alone.
Related: Clinical Peptide Therapy Certification.
Want expert eyes on your peptide protocols every month? Explore the Peptide University practitioner membership.
Continue the work
From perspective to clinical practice
The frameworks in this article are taught in depth inside our Certification curriculum and refined every week inside the Inner Circle.
